They PR'd in the beginning of May that they had a POTENTIAL investment coming from a meeting in London at the end of May. They did not PR the results of that meeting or whether it actually happened so there is no way to say they have a $23MM now - it would be super out of character for a company which PRs "African economies are growing" and PR'd "we might get financing" to not PR "we got financing". Even assuming some margin on the Revolt it is tough to say that they will be instantly profitable without assuming a cost of financing. So far, the financing from dilutive equity issuance has been so expensive as to be profitable with those terms would be near impossible. Neither of us know but that is a stretch especially since there is no forecast of future orders past the alleged potential $20MM+. Goldman (Rob Goldman not Goldman Sachs) initiated a price target of $.09 as it is a one man shop who is paid to write pumps on OTC companies based on information they give him in PRs, disclosures, and some rough technical analysis. He does not visit the companies, perform extra due diligence etc. A disclaimer on his site says "Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms". He never makes negative recommendations. His resume adds credibility but it's pretty hard to stay in legitimate Wall Street as you get older without being a superstar and I guess he has to eat - if you know anyone who is a SUCCESSFUL buy-side or sell-side stock analyst ask them if they would ever switch jobs to write paid research for OTC penny stocks. In theory he could as he is not paid to be positive but paid to write but if he writes negative he does not get repeat business. If you look at his website, the ALYI articles are under "sponsored research." Don't take my opinion- ask your legitimate broker what he thinks about Rob Goldman's small cap research. I agree - you might get a real gain but I am sure this company will never have positive shareholder equity prior to it going silent like its partner ANCE.
